Rho, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Chapel Hill NC United States (1984)

Organization Overview

First Clinical Trial
2006
NCT00122980
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Rho Federal Systems Division, Inc. | Rho, Inc. | Rho Incorporated

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Anemia, Sickle Cell (Phase 3)

Anthrax (Phase 2)

Hematologic Diseases (Phase 3)

Hemochromatosis (Phase 3)

Influenza, Human (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Stroke (Phase 3)

Temporomandibular Joint Disorders (Phase 2)

Temporomandibular Joint Dysfunction Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 29